Preclinical data further indicate that serum HMGB1 levels may serve as a biomarker to guide personalized anti‐inflammatory treatment: elevated postoperative HMGB1 in children with biliary atresia correlates with reduced 2‐year native liver survival, suggesting potential benefits of glucocorticoids or glycyrrhizin for specific subgroups [212]. This evidence concerns the gene HMGB1 and biliary atresia.